Indications：Burn Wounds
GM-XAN006
GM-XAN006 has completed preclinical experiments, demonstrating its ability to accelerate the wound healing process in burn-injured rats.
**Introduction to Burn Wounds**
Burn injuries are categorized into first to third-degree burns based on the depth and extent of the burn. Third-degree burns, characterized by excessive damage to the skin and nerves, often require grafting or amputation for treatment. Second-degree burns are further classified into superficial and deep, with deep second-degree burns affecting the dermis and potentially leading to scarring, sometimes requiring grafting.
Superficial second-degree burns, limited to the shallow dermal layer, typically heal faster and are less prone to scarring. In treatment, topical antimicrobial ointments and dressings such as silver sulfadiazine, chlorhexidine, or other antibiotic ointments are commonly used to protect wounds. Dressing options include waterproof, antimicrobial, and moisture-maintaining varieties.
However, the current focus in therapeutic development often emphasizes medical device dressings. There remains a significant market gap for medications that can promote wound healing, highlighting the need for a comprehensive approach in burn wound care that combines the strengths of various treatment modalities to provide optimal care for patients.
**Market Overview**
WHO estimates that around 11 million burn injuries occur each year globally. According to the market analysis report of Future market insights, the global burn care market size was valued at USD 1.8 billion in 2023, and it is estimated to exceed USD 3.1 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The advanced wound dressings segment held the largest market share of 42.74% in 2023 (Grand view research 2023). North America accounted for 51.6% of the global sales for the burn care in 2022, and Asia Pacific region is expected to be the fasted growing market (Grand view research 2023).